1-4 of 4
Evelyn Barnett
Close
Sort by
Journal Articles

Outcomes Following Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma Patients at Risk of Bleeding Events Because of Multiple Comorbidities or Treatment: A Post-Hoc Subgroup Analysis of the SPRINT (MCL-002) Trial

Marek Trneny, Thierry Lamy, MDPhD, Jan Walewski, MD PhD, David Belada, MD PhD, Jiri Mayer, John A Radford, MB ChB, MRCP, MD FRCP, Wojciech Jurczak, MD PhD, Franck Morschhauser, Julia Alexeeva, MD, Simon A. Rule, MD, Boris V Afanasyev, Professor, Kamil Kaplanov, Antoine Thyss, MD, Alexej Kuzmin, MD, Sergey Voloshin, MD, Kazimierz Kuliczkowski, prof., Agnieszka Giza, MD, Noel Milpied, MD PhD, Caterina Stelitano, MD, Reinhard Marks, MD, Lorenz Trümper, MD, Tsvetan Biyukov, MD, Evelyn Barnett, Marie-Laure Casadebaig Bravo, MSc, Luca Arcaini, MD
Journal: Blood
Blood (2016) 128 (22): 2978.
https://doi.org/10.1182/blood.V128.22.2978.2978
Published: 2016
Journal Articles

Effectiveness of Lenalidomide in Patients with Mantle Cell Lymphoma Who Relapsed/Progressed after or Were Refractory/Intolerant to Ibrutinib: The MCL-004 Study

Michael Wang, MD, Peter Martin, MD, Tycel Phillips, MD, Andre Goy, MD, Izidore S Lossos, MD, Simon A. Rule, MD, Mehdi Hamadani, MD, Nilanjan Ghosh, MD PhD, Craig B. Reeder, MD, Evelyn Barnett, Marie-Laure Casadebaig Bravo, MSc, Stephen J. Schuster, MD
Journal: Blood
Blood (2016) 128 (22): 1786.
https://doi.org/10.1182/blood.V128.22.1786.1786
Published: 2016
Journal Articles

Target Engagement, Pathway Inhibition, and Efficacy Of The Bruton’s Tyrosine Kinase (Btk) Inhibitor CC-292

Daniel W Pierce, Sabine Ponader, PhD, Kumudha Balakrishnan, Varsha Gandhi, PhD, William G. Wierda, MD, Susan O'Brien, MD, Carla Heise, PhD, Mariana Nacht, PhD, Sharon Aslanian, Xiping Liu, Sean Hong, Shijuan Wu, Marianna Zavodovskaya, MS, Jeffrey Marine, Evelyn Barnett, Pilar Nava-Parada, Jay Mei, MD, Rajesh Chopra, MD, Jan A. Burger, MD, PhD, Juswinder Singh
Journal: Blood
Blood (2013) 122 (21): 4169.
https://doi.org/10.1182/blood.V122.21.4169.4169
Published: 2013
Journal Articles

Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Jennifer R. Brown, MD, PhD, Wael A. Harb, MD, Brian T. Hill, MD, PhD, Janice Gabrilove, MD, Jeff P. Sharman, MD, Marshall T. Schreeder, MD, MPH, Paul M. Barr, MD, James M. Foran, MD, Thomas P. Miller, MD, Jan A. Burger, MD, PhD, Kevin R. Kelly, MD, PhD, Daruka Mahadevan, MD, PhD, Shuo Ma, MD, PhD, Evelyn Barnett, Jeffrey Marine, Pilar Nava-Parada, Ada Azaryan, Jay Mei, MD, Thomas J. Kipps, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 1630.
https://doi.org/10.1182/blood.V122.21.1630.1630
Published: 2013